Dupilumab-associated hypereosinophilia in severe asthma

Dupilumab is a monoclonal antibody directed at the shared alpha subunit of interleukin-4 and −13 receptors, and is subsidised in Australia for severe uncontrolled asthma 1–4. Dupilumab inhibits eosinophil migration into tissues, but does not inhibit eosinophil production or release from bone marrow, resulting in a transient increase in circulating eosinophils 1. There have been reports of symptomatic dupilumab-associated hypereosinophilia 3, 5. Footnotes This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article. Conflict of interest: Unrelated to this study, Mark Hew has received grants and personal fees from GlaxoSmithKline, AstraZeneca, Sanofi, Novartis, Teva and Chiesi, all paid to his employer Alfred Health. Conflict of interest: Unrelated to this study, Eve Denton declares project grants to her institution from AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Teva and Seqirus and speaker fees from Sanofi. Conflict of interest: Unrelated to this study, in the past 36 months Celia Zubrinich has received speaker fees and grants from Novartis, Mylan, Seqirus, Inovating and Inside Practice. Conflict of interest: Unrelated to this study in the past 36 months, Asger Sverrild has received research grants paid to employer from AstraZeneca and speaker fees from AstraZeneca and Sanofi. Conflict of interest: Asger Sverrild serves on advisory board for GlaxoSmithKline and Sanofi-Regeneron with honoraria made to institution. Conflict of interest: Unrelated to this study, Joy Lee has received speaker fees from AstraZeneca, Sanofi, GSK as well as serving on the board of the National Allergy Centre of Excellence. Conflict of interest: All authors have completed the ICMJE uniform disclosure form available at www. icmje. org/coidisclosure. pdf1 1: http: //www. icmje. org/coidisclosure. pdf